Pharmicell Co., Ltd., established in 2002, is a South Korean biopharmaceutical company renowned for developing the world's first stem cell therapy, Hearticellgram-AMI, approved by the Korean Ministry of Food and Drug Safety in 2011. Specializing in autologous bone marrow-derived mesenchymal stem cell therapies, Pharmicell's pipeline includes treatments for acute myocardial infarction, liver cirrhosis, erectile dysfunction, and various cancers . Beyond therapeutics, the company operates in the biochemical sector, producing raw material pharmaceutical intermediates like nucleosides and mPEGs, and offers stem cell-based cosmetics and banking services . With a commitment to advancing human health, Pharmicell continues to innovate at the intersection of biotechnology and medicine.
